236 related articles for article (PubMed ID: 19679546)
1. Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells.
Fan HY; Liu Z; Paquet M; Wang J; Lydon JP; DeMayo FJ; Richards JS
Cancer Res; 2009 Aug; 69(16):6463-72. PubMed ID: 19679546
[TBL] [Abstract][Full Text] [Related]
2. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS
Oncogene; 2011 Aug; 30(32):3522-36. PubMed ID: 21423204
[TBL] [Abstract][Full Text] [Related]
3. Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis.
Richards JS; Fan HY; Liu Z; Tsoi M; Laguë MN; Boyer A; Boerboom D
Oncogene; 2012 Mar; 31(12):1504-20. PubMed ID: 21860425
[TBL] [Abstract][Full Text] [Related]
4. Selective expression of KrasG12D in granulosa cells of the mouse ovary causes defects in follicle development and ovulation.
Fan HY; Shimada M; Liu Z; Cahill N; Noma N; Wu Y; Gossen J; Richards JS
Development; 2008 Jun; 135(12):2127-37. PubMed ID: 18506027
[TBL] [Abstract][Full Text] [Related]
5. Targeted disruption of Pten in ovarian granulosa cells enhances ovulation and extends the life span of luteal cells.
Fan HY; Liu Z; Cahill N; Richards JS
Mol Endocrinol; 2008 Sep; 22(9):2128-40. PubMed ID: 18606860
[TBL] [Abstract][Full Text] [Related]
6. Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS
Kun EHS; Tsang YTM; Lin S; Pan S; Medapalli T; Malpica A; Richards JS; Gershenson DM; Wong KK
Sci Rep; 2020 Nov; 10(1):20678. PubMed ID: 33244099
[TBL] [Abstract][Full Text] [Related]
7. Three types of metaplasia model through Kras activation, Pten deletion, or Cdh1 deletion in the gastric epithelium.
Kinoshita H; Hayakawa Y; Konishi M; Hata M; Tsuboi M; Hayata Y; Hikiba Y; Ihara S; Nakagawa H; Ikenoue T; Ushiku T; Fukayama M; Hirata Y; Koike K
J Pathol; 2019 Jan; 247(1):35-47. PubMed ID: 30168144
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.
Collins MA; Bednar F; Zhang Y; Brisset JC; Galbán S; Galbán CJ; Rakshit S; Flannagan KS; Adsay NV; Pasca di Magliano M
J Clin Invest; 2012 Feb; 122(2):639-53. PubMed ID: 22232209
[TBL] [Abstract][Full Text] [Related]
9. Global or Granulosa Cell-Specific Pten Mutations in Combination with Elevated FSH Levels Fail to Cause Ovarian Tumours in Mice.
Upton DH; Walters KA; Allavena RE; Jimenez M; Desai R; Handelsman DJ; Allan CM
Horm Cancer; 2016 Dec; 7(5-6):316-326. PubMed ID: 27506975
[TBL] [Abstract][Full Text] [Related]
10. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
[TBL] [Abstract][Full Text] [Related]
11. Minireview: physiological and pathological actions of RAS in the ovary.
Fan HY; Richards JS
Mol Endocrinol; 2010 Feb; 24(2):286-98. PubMed ID: 19880654
[TBL] [Abstract][Full Text] [Related]
12. PTEN loss and KRAS activation cooperate in murine biliary tract malignancies.
Marsh V; Davies EJ; Williams GT; Clarke AR
J Pathol; 2013 Jun; 230(2):165-73. PubMed ID: 23483557
[TBL] [Abstract][Full Text] [Related]
13. MUC1 positive, Kras and Pten driven mouse gynecologic tumors replicate human tumors and vary in survival and nuclear grade based on anatomical location.
Tirodkar TS; Budiu RA; Elishaev E; Zhang L; Mony JT; Brozick J; Edwards RP; Vlad AM
PLoS One; 2014; 9(7):e102409. PubMed ID: 25078979
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression.
Laguë MN; Paquet M; Fan HY; Kaartinen MJ; Chu S; Jamin SP; Behringer RR; Fuller PJ; Mitchell A; Doré M; Huneault LM; Richards JS; Boerboom D
Carcinogenesis; 2008 Nov; 29(11):2062-72. PubMed ID: 18687666
[TBL] [Abstract][Full Text] [Related]
15. Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer.
Zhang L; Ma T; Brozick J; Babalola K; Budiu R; Tseng G; Vlad AM
Oncogene; 2016 Sep; 35(38):5010-20. PubMed ID: 26973247
[TBL] [Abstract][Full Text] [Related]
16. CRL4DCAF1 is required in activated oocytes for follicle maintenance and ovulation.
Yu C; Xu YW; Sha QQ; Fan HY
Mol Hum Reprod; 2015 Feb; 21(2):195-205. PubMed ID: 25371539
[TBL] [Abstract][Full Text] [Related]
17. PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine.
Davies EJ; Marsh Durban V; Meniel V; Williams GT; Clarke AR
J Pathol; 2014 May; 233(1):27-38. PubMed ID: 24293351
[TBL] [Abstract][Full Text] [Related]
18. The effect of androgens on ovarian follicle maturation: Dihydrotestosterone suppress FSH-stimulated granulosa cell proliferation by upregulating PPARγ-dependent PTEN expression.
Chen MJ; Chou CH; Chen SU; Yang WS; Yang YS; Ho HN
Sci Rep; 2015 Dec; 5():18319. PubMed ID: 26674985
[TBL] [Abstract][Full Text] [Related]
19. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
20. Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival.
Mullany LK; Liu Z; King ER; Wong KK; Richards JS
Endocrinology; 2012 Apr; 153(4):1638-48. PubMed ID: 22396451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
